563 related articles for article (PubMed ID: 27197156)
1. Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.
Tokheim C; Bhattacharya R; Niknafs N; Gygax DM; Kim R; Ryan M; Masica DL; Karchin R
Cancer Res; 2016 Jul; 76(13):3719-31. PubMed ID: 27197156
[TBL] [Abstract][Full Text] [Related]
2. Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures.
Kumar S; Clarke D; Gerstein MB
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):18962-18970. PubMed ID: 31462496
[TBL] [Abstract][Full Text] [Related]
3. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
[TBL] [Abstract][Full Text] [Related]
4. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
5. Understanding the impacts of missense mutations on structures and functions of human cancer-related genes: A preliminary computational analysis of the COSMIC Cancer Gene Census.
Malhotra S; Alsulami AF; Heiyun Y; Ochoa BM; Jubb H; Forbes S; Blundell TL
PLoS One; 2019; 14(7):e0219935. PubMed ID: 31323058
[TBL] [Abstract][Full Text] [Related]
6. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types.
Chen T; Wang Z; Zhou W; Chong Z; Meric-Bernstam F; Mills GB; Chen K
BMC Genomics; 2016 Jun; 17 Suppl 2(Suppl 2):394. PubMed ID: 27356755
[TBL] [Abstract][Full Text] [Related]
7. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing reveals recurrent somatic mutation networks in cancer.
Liu X; Wang J; Chen L
Cancer Lett; 2013 Nov; 340(2):270-6. PubMed ID: 23153794
[TBL] [Abstract][Full Text] [Related]
9. Performance characteristics of the AmpliSeq Cancer Hotspot panel v2 in combination with the Ion Torrent Next Generation Sequencing Personal Genome Machine.
Butler KS; Young MY; Li Z; Elespuru RK; Wood SC
Regul Toxicol Pharmacol; 2016 Feb; 74():178-86. PubMed ID: 26387931
[TBL] [Abstract][Full Text] [Related]
10. An analysis of mutational signatures of synonymous mutations across 15 cancer types.
Bin Y; Wang X; Zhao L; Wen P; Xia J
BMC Med Genet; 2019 Dec; 20(Suppl 2):190. PubMed ID: 31815613
[TBL] [Abstract][Full Text] [Related]
11. Identification and analysis of mutational hotspots in oncogenes and tumour suppressors.
Baeissa H; Benstead-Hume G; Richardson CJ; Pearl FMG
Oncotarget; 2017 Mar; 8(13):21290-21304. PubMed ID: 28423505
[TBL] [Abstract][Full Text] [Related]
12. Oncogenes and tumor suppressor genes: comparative genomics and network perspectives.
Zhu K; Liu Q; Zhou Y; Tao C; Zhao Z; Sun J; Xu H
BMC Genomics; 2015; 16 Suppl 7(Suppl 7):S8. PubMed ID: 26099335
[TBL] [Abstract][Full Text] [Related]
13. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
Pécuchet N; Legras A; Laurent-Puig P; Blons H
Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
[TBL] [Abstract][Full Text] [Related]
14. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes.
Cheng F; Zhao J; Zhao Z
Brief Bioinform; 2016 Jul; 17(4):642-56. PubMed ID: 26307061
[TBL] [Abstract][Full Text] [Related]
15. Mutation Drivers of Immunological Responses to Cancer.
Porta-Pardo E; Godzik A
Cancer Immunol Res; 2016 Sep; 4(9):789-98. PubMed ID: 27401919
[TBL] [Abstract][Full Text] [Related]
16. High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification.
Velmurugan KR; Varghese RT; Fonville NC; Garner HR
Oncogene; 2017 Nov; 36(46):6383-6390. PubMed ID: 28759038
[TBL] [Abstract][Full Text] [Related]
17. Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.
Harris KL; Myers MB; McKim KL; Elespuru RK; Parsons BL
Environ Mol Mutagen; 2020 Jan; 61(1):152-175. PubMed ID: 31469467
[TBL] [Abstract][Full Text] [Related]
18. Identifying Driver Interfaces Enriched for Somatic Missense Mutations in Tumors.
Ozturk K; Carter H
Methods Mol Biol; 2019; 1907():51-72. PubMed ID: 30542990
[TBL] [Abstract][Full Text] [Related]
19. Computational Approaches to Prioritize Cancer Driver Missense Mutations.
Zhao F; Zheng L; Goncearenco A; Panchenko AR; Li M
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30037003
[TBL] [Abstract][Full Text] [Related]
20. CHASMplus Reveals the Scope of Somatic Missense Mutations Driving Human Cancers.
Tokheim C; Karchin R
Cell Syst; 2019 Jul; 9(1):9-23.e8. PubMed ID: 31202631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
